Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLADIS: Effects of CLADribine tablets on the Immune Synapse in Relapsing Multiple Sclerosis
2025-521910-24-00Phase 4Authorised
- Sponsor
- Aristotle University of Thessaloniki
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in multiple sclerosis (MS), sponsored by Aristotle University of Thessaloniki. Primary endpoint: Change in immune synapse molecule expression at 12 months. Planned start Apr 2026; status: authorised.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2025-521910-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521910-24-00.